CN109640986A - 用于治疗癌症的硫代乙内酰脲雄激素受体拮抗剂 - Google Patents

用于治疗癌症的硫代乙内酰脲雄激素受体拮抗剂 Download PDF

Info

Publication number
CN109640986A
CN109640986A CN201780051671.2A CN201780051671A CN109640986A CN 109640986 A CN109640986 A CN 109640986A CN 201780051671 A CN201780051671 A CN 201780051671A CN 109640986 A CN109640986 A CN 109640986A
Authority
CN
China
Prior art keywords
compound
oxo
thioxo
diazaspiro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780051671.2A
Other languages
English (en)
Chinese (zh)
Inventor
G.C.比格南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN109640986A publication Critical patent/CN109640986A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780051671.2A 2016-08-22 2017-08-22 用于治疗癌症的硫代乙内酰脲雄激素受体拮抗剂 Pending CN109640986A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
US62/377932 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN109640986A true CN109640986A (zh) 2019-04-16

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051671.2A Pending CN109640986A (zh) 2016-08-22 2017-08-22 用于治疗癌症的硫代乙内酰脲雄激素受体拮抗剂

Country Status (12)

Country Link
US (1) US20190209539A1 (enExample)
EP (1) EP3500259A1 (enExample)
JP (1) JP2019528290A (enExample)
KR (1) KR20190040030A (enExample)
CN (1) CN109640986A (enExample)
AU (1) AU2017316756A1 (enExample)
BR (1) BR112019003406A2 (enExample)
CA (1) CA3034449A1 (enExample)
MA (1) MA45992A (enExample)
MX (1) MX2019002097A (enExample)
RU (1) RU2019108092A (enExample)
WO (1) WO2018037342A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403624A (zh) * 2022-09-30 2022-11-29 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032644B (zh) * 2017-08-07 2021-08-10 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
BR112021015122A2 (pt) 2019-02-01 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Cristal de composto de diariltio-hidantoína

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884057A (zh) * 2010-02-16 2013-01-16 亚拉冈制药公司 雄激素受体调节剂及其用途
US20150274693A1 (en) * 2012-10-26 2015-10-01 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884057A (zh) * 2010-02-16 2013-01-16 亚拉冈制药公司 雄激素受体调节剂及其用途
US20150274693A1 (en) * 2012-10-26 2015-10-01 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403624A (zh) * 2022-09-30 2022-11-29 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Also Published As

Publication number Publication date
WO2018037342A1 (en) 2018-03-01
RU2019108092A (ru) 2020-09-22
US20190209539A1 (en) 2019-07-11
MA45992A (fr) 2019-06-26
MX2019002097A (es) 2019-05-15
JP2019528290A (ja) 2019-10-10
KR20190040030A (ko) 2019-04-16
AU2017316756A1 (en) 2019-02-21
BR112019003406A2 (pt) 2019-05-21
CA3034449A1 (en) 2018-03-01
RU2019108092A3 (enExample) 2020-11-30
EP3500259A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
EP4157836B1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN118574835A (zh) 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
JP6327713B2 (ja) 急性骨髄性白血病の治療又は再発抑制剤
JP6507234B2 (ja) ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
JP2019508404A (ja) 癌患者の層別化および癌治療のための化合物、組成物および方法
CN107635404B (zh) 用于治疗疾病的mct4抑制剂
TW201524952A (zh) Ｋｒａｓ ｇ１２ｃ之共價抑制劑
KR20160012195A (ko) Bet 억제제로서의 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도
EA028035B1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
US20190241542A1 (en) Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
CN114206853A (zh) 用于治疗的parp14的靶向蛋白质降解
CN109640986A (zh) 用于治疗癌症的硫代乙内酰脲雄激素受体拮抗剂
CN110167556A (zh) 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
JP2024528073A (ja) 有機ピリジン－ピラゾール化合物及びその使用
US20220088005A1 (en) Bromodomain inhibitors for androgen receptor-driven cancers
WO2023024545A1 (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
JP2024528072A (ja) イミダゾール有機化合物及び炎症性腸疾患に対するその使用
HK40045061A (en) Erbb receptor inhibitors
KR20250154499A (ko) Parp 억제제로서의 치환된 질소-함유 트리시클릭 화합물 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190416

WD01 Invention patent application deemed withdrawn after publication